• Explore /
  • Poster
  • / IMRT followed by pembrolizumab in the adjuvant setting in anaplastic cancer of the thyroid (IMPAACT): Phase II trial adjuvant pembrolizumab after IMRT in ATC.

IMRT followed by pembrolizumab in the adjuvant setting in anaplastic cancer of the thyroid (IMPAACT): Phase II trial adjuvant pembrolizumab after IMRT in ATC.

Abstract Poster

Authors

null

Maria E. Cabanillas

The University of Texas MD Anderson Cancer Center, Houston, TX

Maria E. Cabanillas , Gary Brandon Gunn , Mark E. Zafereo , Rui Jennifer Wang , Priyanka C. Iyer , Anastasios Maniakas , Michael T Spiotto , Ramona Dadu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Head and Neck Cancer

Track

Head and Neck Cancer

Sub Track

Other Head and Neck Cancer (Salivary, Thyroid)

Clinical Trial Registration Number

NCT05059470

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS6117)

DOI

10.1200/JCO.2023.41.16_suppl.TPS6117

Abstract #

TPS6117

Poster Bd #

101a

Abstract Disclosures

Similar Posters

First Author: Paul Eliezer Oberstein

First Author: Inkeun Park

First Author: Changying Guo

First Author: Timothy Jay Price